Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

The U.S. Food and Drug Administration (FDA) has approved Journavx, the first opioid-free prescription drug for moderate to ...

“I believe JOURNAVX could redefine the management of pain and become a foundational treatment option for people with all types of moderate-to-severe acute pain, where options aside from opioids ...

We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...

To answer those questions and more, Host Ira Flatow talks with one of the top researchers in the field, Dr. Jamie Hartmann-Boyce, assistant professor of health policy and management at the ...

Writing in the journal Frontiers in Conservation Science, former Montana bear management specialist ... Administration approved a new pain medicine called Journavx (suzetrigine), made by Vertex ...

RBC Capital notes that the clinical review documents associated with Sector Perform-rated Vertex Pharmaceuticals (VRTX)’ recent approval of ...

Dr. Jason Busse and I are pleased to present a project at McMaster on the safe and effective use of opioids for chronic pain ...

Sensory neurons that respond to temperature, touch and pain have ways of adapting to repeated stimuli that can change how a ...

Acute pain management in the older adult is both challenging and rewarding. This review addresses the difficulty with assessment of pain in the older adult, variations in the pain experience of ...